Published online Aug 7, 2025. doi: 10.3748/wjg.v31.i29.110004
Revised: June 13, 2025
Accepted: July 8, 2025
Published online: August 7, 2025
Processing time: 69 Days and 16.4 Hours
Ultra-low rectal cancer (ULRC), defined as a lesion located within 5 cm of the anal verge, poses considerable clinical challenges because the treatment decision must balance oncological eradication with preservation of anal function. Historically, abdominoperineal resection (APR) has served as a standard approach for tumor eradication in these patients, but a permanent stoma significantly reduces pa
To address a persistent debate in ULRC management, we compared ISR and APR outcomes through rigorous methodology.
A retrospective analysis of patients undergoing surgery at three centers in China between 2012 and 2023 was performed with propensity score matching (PSM).
A total of 803 patients (435 in the ISR group and 368 in the APR group) met the inclusion criteria, with 289 comprising each of the two groups after PSM. Over a median follow-up of 47.2 months, the absolute 5-year overall survival (OS) improved by 6.7% with ISR (80.8% vs 74.1%, P = 0.032). Cox regression analysis confirmed ISR (HR = 0.554, 95%CI: 0.371-0.828, P = 0.004) as an independent protective factor for OS and reduced local recurrence (9.5% vs 12.9%, P = 0.019). With respect to short-term complications, despite higher anastomotic leakage rates (11.4% vs 1.0%), ISR significantly reduced total complications (29.4% vs 42.2%, P = 0.001) and hospitalization duration (9.8 days vs 12.9 days, P < 0.001). Moreover, incision infection, urinary retention, circumferential resection margins, and hospitalization time were greater in the APR group (P < 0.05).
The long-term prognosis of ULRC treated with ISR is excellent, with no increase in overall surgical complications or hospital stay duration, indicating that ISR is a feasible alternative to APR for managing ULRC.
Core Tip: As the largest propensity score-matched study comparing intersphincteric resection (ISR) and abdominoperineal resection (APR), we minimized selection bias by balancing 13 covariates across 803 patients (289 matched pairs). ISR demonstrated a 6.7% absolute improvement in 5-year overall survival (80.8% vs 74.1%, HR = 0.554, P = 0.004) and reduced local recurrence (9.5% vs 12.9%, P = 0.019), establishing its oncologic superiority. Despite higher anastomotic leakage rates (11.4% vs 1.0%), ISR significantly reduced total complications (29.4% vs 42.2%, P = 0.001) and hospitalization duration (9.8 days vs 12.9 days, P < 0.001), supporting its role as the preferred sphincter-preserving alternative to APR.